Diagnostic Center | August 26, 2024
Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
The proposed hospital will have a bed capacity of 300 beds and the investment in the project is expected to be around Rs. 500 crore
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Minister was briefed on the nationwide dengue situation
To implement AI-enabled chest X-ray solution for TB & COVID-19 screening in Maharashtra through Unitaid funding
ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra
Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders
Subscribe To Our Newsletter & Stay Updated
